Molecular Markers in Rathke’s Cleft Cysts Correlate With Endocrine Deficits

Rathke’s cleft cysts are benign sellar lesions often discovered incidentally during imaging for unrelated symptoms, yet they carry a significant risk of morbidity when they compress the pituitary gland or hypothalamus [1]. While many remain asymptomatic, symptomatic cases frequently present with headaches, visual disturbances, and endocrine dysfunction, including a 14% prevalence of permanent arginine vasopressin deficiency (the underlying cause of central diabetes insipidus, characterized by an inability to concentrate urine) following surgical intervention [2]. Distinguishing these cysts from more aggressive lesions like craniopharyngiomas remains a diagnostic challenge, as both share similar anatomical locations and clinical presentations [3]. Current management relies heavily on clinical symptoms and magnetic resonance imaging, but the underlying molecular mechanisms driving cyst pathogenesis and associated hormonal deficits are poorly understood [4]. To address this gap, researchers recently conducted a retrospective analysis evaluating how specific molecular markers correlate with these clinical manifestations, aiming to improve diagnostic precision and better predict postoperative endocrine outcomes.